The Annual General Meeting of H. Lundbeck A/S was held on 30 March 2004 at Bella Center.
At the General Meeting the report from the Supervisory Board on the activities of the Company during the previous financial year was noted, the annual report was approved, and the Supervisory Board and the Board of Management were discharged from liability.
The General Meeting approved the Supervisory Board’s proposal for distribution of profit with DKK 1.77 per share of nominal value DKK 5 each share.
Flemming Lindeløv, Lars Bruhn, Peter Kürstein, and Jes Østergaard and Mats Pettersson were all re-elected as members of the Supervisory Board. Thorleif Krarup was elected as new member of the Supervisory Board. The Supervisory Board constituted itself after the General Meeting with Flemming Lindeløv as the chairman and Thorleif Krarup as the vice-chairman.
Furthermore, the Supervisory Board established an audit committee with the duty to review the Company’s financial reporting procedures, financial reporting and other financial information published by the Company. The audit committee shall also review internal controls in relation to overall balance and transparency in the financial reporting and the reports submitted by the auditors.
Flemming Lindeløv, Thorleif Krarup and Peter Kürstein were appointed members of the audit committee.
In addition, the Supervisory Board established a remuneration committee to provide the members of the Supervisory Board with the best possible basis for making decisions concerning the total remuneration package provided to the members of the Executive Management.
Flemming Lindeløv, Mats Pettersson and Jes Østergaard were appointed members of the remuneration committee.
Deloitte, Statsautoriseret Revisionsaktieselskab and Grant Thornton, Statsautoriseret Revisionsaktieselskab were re-elected as auditors for the Company
The proposals of the Supervisory Board under item 6 on the agenda were approved. As a result hereof the Supervisory Board was authorised to acquire own shares in accordance with section 48 of the Danish Public Companies Act. Further, the Articles of Association were amended to the effect that the Company‘s registrar of the Register of Shareholders is Aktiebog Danmark A/S according to the Articles of Association. The Articles of Association were also amended so that the authorisations of the Supervisory Board to increase the Company’s share capital were prolonged in accordance with section 37 of the Danish Public Companies Act until 30 March 2009. Moreover, for the purpose of good order the articles regarding warrants of the Articles of Association were revised in consequence of the Supervisory Board’s utilization hereof 9 December 2003.
There were no further items on the agenda.
The Supervisory Board
The content of this release will have no influence on the Lundbeck Group’s expectations for the financial result for 2004.
Investor contact
-Â Steen Juul Jensen, Vice President, tel +45 36 43 30 06
-Â Jacob Tolstrup, Investor Relations Manager, tel +45 36 43 30 79.
Media contact
-Â Hans Henrik Munch-Jensen, CFO, tel +45 36 30 15 11, ext. 32660.
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2003, the company’s revenue was DKK 9.9 billion. The number of employees is approx. 5,300.
Ottiliavej 9
DK-2500 Copenhagen Valby
Fax +45 36 30 19 40
Disclaimer & Privacy statement